How Chemotherapy Works

Unlike radiation therapy which targets a specific location or surgery which removes a particular tumor, chemotherapy drugs are systemic treatments. When injected into a vein, taken as a pill, or administered through other routes, these drugs dissolve into the bloodstream and circulate throughout the body via the cardiovascular system. This circulation occurs continuously as the heart pumps blood through approximately 60,000 miles of blood vessels, carrying the chemotherapy agents to organs, tissues, and hidden clusters of cancer cells that may have spread far from the original tumor site.

This whole-body circulation is chemotherapy's greatest strength when dealing with metastatic cancer—disease that has spread beyond its starting point. Cancer cells that have broken away from a primary tumor and traveled to distant organs like the liver, lungs, or bones receive exposure to the treatment drugs as blood flows through these areas. The drugs don't need to "know" where cancer cells are hiding; they simply travel everywhere blood goes.

The circulation continues for hours or days depending on the specific drug, with the liver and kidneys eventually filtering the chemicals from the bloodstream and eliminating them through urine and stool. During this circulation window, cancer cells throughout the body are exposed to the drugs' effects multiple times as blood repeatedly cycles through the body—your heart pumps your entire blood volume through your circulatory system roughly once per minute.

Cancer cells share one defining characteristic: they divide and multiply much faster than most normal cells in the body. While a typical liver cell might divide once every year or two, a cancer cell might divide every few days or even hours. Chemotherapy drugs are designed to exploit this difference—they preferentially damage cells that are actively going through the division process. The drugs don't inherently "recognize" cancer versus healthy tissue; instead, they attack based on the rate of cell division.

Different chemotherapy drugs target different phases of the cell division cycle. Some attack cells during DNA replication when the genetic material is being copied. Others strike during mitosis when the chromosomes are separating into two new cells. A few target cells during the growth phases between divisions when they're building up the proteins and structures needed for the next round of division. By hitting multiple phases, combination chemotherapy regimens increase the chances of catching cancer cells at vulnerable moments.

Unfortunately, some healthy cells also divide rapidly and become collateral damage. Hair follicle cells divide every few days to grow hair, which is why chemotherapy often causes hair loss. Bone marrow cells that produce blood cells, intestinal lining cells that replace themselves every few days, and cells in the mouth and reproductive system also divide frequently. These rapidly dividing healthy cells suffer damage alongside cancer cells, producing the characteristic side effects of chemotherapy treatment.

At the molecular level, chemotherapy drugs physically interfere with the DNA replication and cell division machinery. Some drugs, called alkylating agents, attach chemical groups directly onto DNA strands, creating abnormal bonds that prevent the double helix from unzipping properly for copying. Others, called antimetabolites, masquerade as the building blocks of DNA—they look similar enough to adenine, thymine, guanine, or cytosine that the cell's copying machinery incorporates them, but different enough that they jam the process like using the wrong Lego pieces.

A different class called topoisomerase inhibitors blocks the enzymes that manage DNA's tightly coiled structure. During replication, DNA must unwind from its compact form, and topoisomerase enzymes create temporary breaks in the strands to release tension—like cutting a twisted rubber band to let it uncoil. When chemotherapy blocks these enzymes, the DNA becomes hopelessly tangled, and replication grinds to a halt.

Mitotic inhibitors take a different approach by attacking the microtubule structures that pull chromosomes apart during cell division. These drugs bind to tubulin proteins and either prevent them from assembling into the rope-like structures needed to separate chromosomes, or stabilize them so rigidly they can't disassemble. Either way, the dividing cell gets stuck with chromosomes frozen in place, unable to complete the split into two daughter cells. The cell recognizes something has gone catastrophically wrong and typically initiates its self-destruction sequence.

When chemotherapy inflicts enough damage on a cell's DNA or division machinery, the cell doesn't simply limp along in a damaged state. Cells have evolved sophisticated quality control systems that monitor for errors during replication and division. Proteins like p53 act as checkpoint guardians, detecting DNA damage and halting the cell cycle until repairs can be made. If the damage exceeds repair capacity—as chemotherapy intends—these guardian proteins trigger apoptosis, the cell's programmed death sequence.

Apoptosis is an orderly dismantling process distinct from necrosis (traumatic cell death). The cell systematically breaks down its internal structures, condenses its nucleus, fragments its DNA into neat pieces, and packages itself into membrane-bound blebs that neighboring cells and immune macrophages can safely consume. This controlled death prevents the cell from spilling inflammatory contents into surrounding tissue and avoids the damage that uncontrolled cell rupture would cause.

Cancer cells evolve mechanisms to evade apoptosis—mutations that disable p53 or amplify survival signals allow them to ignore damage and keep dividing. This is one reason why some cancers resist chemotherapy: their cells have effectively disabled the self-destruct button. Higher doses or different drug combinations may overwhelm even these resistant mechanisms, though this also increases damage to healthy cells. When chemotherapy works effectively, tumors shrink as millions of cancer cells undergo apoptosis faster than the remaining cancer cells can divide to replace them.

Chemotherapy is administered in cycles rather than continuously—a typical pattern might be treatment for one to three days, followed by two to three weeks of rest, then repeating. This cycling approach exists for several critical reasons. First, not all cancer cells are dividing at the same moment; some are resting in dormant phases where chemotherapy can't reach them. By repeating treatments, the drugs catch cells that were dormant during earlier cycles but have since entered active division. Each cycle whittles down the cancer cell population further.

The rest period between cycles allows healthy cells to recover. Because bone marrow, intestinal lining, and other rapidly dividing healthy tissues also suffer damage during treatment, patients need time for these cells to regenerate before the next assault. Blood cell counts typically drop during the week after chemotherapy and gradually recover over the following two to three weeks. Administering the next cycle before adequate recovery would compound the damage, potentially causing dangerous complications like severe anemia, inability to fight infections, or life-threatening bleeding.

The specific timing and number of cycles depend on the cancer type, drug combination, and treatment goals. Some protocols use dose-dense scheduling with shorter rest periods to keep pressure on fast-growing cancers, supported by medications that accelerate blood cell recovery. Others space cycles further apart for slower-growing cancers or when treating elderly patients with reduced resilience. Oncologists monitor blood counts, side effects, and tumor response throughout treatment, adjusting the schedule if complications arise or if scans show the cancer isn't responding adequately.